Nevertheless, this investigation represents a conceptual advancement as the first demonstration of untargeted metabolomics’ novel utility in addressing diagnostic challenges within the PSA gray zone (4-10ng/ml) - a clinically critical yet diagnostic ambiguous parameter in prostate cancer screening. This evidence concerns the gene KLK3 and Familial prostate cancer.